C9ORF72 and parkinsonism: Weak link, innocent bystander, or central player in neurodegeneration?

This is the author's manuscript

Original Citation:
C9ORF72 and parkinsonism: Weak link, innocent bystander, or central player in neurodegeneration? / Cavallieri, Francesco*; Mandrioli, Jessica; Rosafio, Francesca; Contardi, Sara; Fasano, Antonio; Menozzi, Elisa; Caponnetto, Claudia; Chiò, Adriano; Valzania, Franco. - In: JOURNAL OF THE NEUROLOGICAL SCIENCES. - ISSN 0022-510X. - 378(2017), pp. 49-51.

Availability:
This version is available http://hdl.handle.net/2318/1673186 since 2018-08-11T18:21:58Z

Published version:
DOI:10.1016/j.jns.2017.04.027

Terms of use:
Open Access
Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)
Letter to the Editor

C9ORF72 and parkinsonism: Weak link, innocent bystander, or central player in neurodegeneration?

Keywords:
Amyotrophic lateral sclerosis Parkinsonism C9ORF72 Levodopa Parkinson's disease

Dear Editor,

C9ORF72 expansion is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) [1]. Although few case reports have been described [2,3], an increasing role of this hexanucleotide expansion in parkinsonism and related disorders has been recently suggested.

We describe a 60 years-old woman admitted with a 3 years history of progressive gait disturbance with frequent falls, urinary incontinence, diffuse bradykinesia and rigidity. The mother and two sisters of the patient died at 57, 59 and 66 years, respectively, due to ALS with bulbar onset. Neurological examination showed mild dysarthric speech, facial hypomimia with astonished expression, slowness of vertical pursuit eyes movements without supranuclear gaze palsy, frontal release signs (snout re.ex and glabellar tap) and symmetric akinetic-rigid par-kinsonism without resting, postural or action tremor. Bilateral symmetric brisk re.exes without clonus, spreading or Hoffman and Babinski signs were also seen; the jaw jerk re.ex was normal. She had a slow, wide-based, apraxic gait, bilateral decreased arm swing, anterocollis and camptocormia with abnormal “pull” test (Video 1). We did not detect neither lower motor neuron signs, nor cerebellar or sensory deficits. In particular no fasciculations, cramps, hypore.exia, or muscular atrophy were seen in upper and lower limbs. Careful examination of bulbar region did not reveal the presence of fasciculations or wasting of the tongue. There was not limbs hypotonia or muscle weakness.

Neurophysiological studies showed increased motor central conduction time while needle electromyography was normal. Brain and spine MRI did not reveal abnormalities. DAT-SPECT showed symmetrically mildly reduced striatal uptake prevalent in left posterior putamen. Neuropsychological assessment showed impairment in executive functions and praxis abilities. Standard blood examinations, infection markers, autoimmune and neoplastic investigations resulted normal. In order to quantify the motor response to levodopa, an acute drug test was performed by oral administration of 200/50 mg of levodopa-carbidopa with an improvement of 45% in Uni.ed Parkinson's Disease Rating Scale (UPDRS) part III score (from 37/108 in Off-drug condition to 21/108 in On-state), mainly on limbs bradykinesia and rigidity. Levodopa's effect was not detected neither on gait impairment nor on postural instability.

Genetic tests were performed: all the coding exons and 50 bp of the flanking intron-exon boundaries of SOD1, VCP, of exon 6 of TARDBP, of exons 14 and 15 of FUS, of exons 2, 11 and 12 of the MATR3, and exons 5, 9, 12, and 14 of OPTN have been polymerase chain reaction (PCR) am-plied, sequenced using the Big-Dye Terminator v3.1 sequencing kit (Applied Biosystems Inc.), and run on an ABI Prism 3130 genetic analyz-er [4–6]. Repeat-primed PCR (RP-PCR) analysis revealed a heterozygous pathological expansion (37 repeats) of the GGGGCC hexanucleotide in C9ORF72 gene (Fig. 1) [4]. We then discovered further information about one of the patient’s sisters that has been followed up in another Italian Centre, which confirmed us the presence of segregation: she was affected by bulbar ALS and had a heterozygous pathological GGGGCC hexanucleotide expansion in C9ORF72 gene. Therapy with
levodopa-carbidopa (300 mg/day) and then with 4 mg rotigotine transdermal patch led to a stable motor response with subsequent development of levodopa-induced oro-buccal dyskinesia (Video 2). At subsequent follow-ups, treatment was slightly adjusted. At 8 years from onset, she did not develop lower motor neuron/cerebellar signs or further cognition involvement.

This case underlines the widening spectrum of C9ORF72-associated diseases ranging from ALS-FTD complex, psychiatric manifestations, to the broad field of movement disorders [7]. As already described, C9ORF72-associated parkinsonism is frequently characterized by atypical features, concomitant motor neuron signs and cognitive impairment [2]. In this case, the onset, characterized by postural instability, gait disturbance and parkinsonism could be compatible with a Progressive Supranuclear Palsy (PSP)-like phenotype, but the association of autonomic dysfunction, anterocollis, pyramidal signs and oro-buccal dyskinesia without supranuclear vertical gaze palsy may be more suggestive of Multiple System Atrophy (MSA) with predominant parkinsonism. Indeed, our patient meets all of the criteria for a possible diagnosis of MSA, PSP and perhaps also Cortico-Basal Degeneration, but does not fulfill criteria for a probable diagnosis [8]. Furthermore, the significant and stable L-DOPA response together with a very mild progression may move towards the evolution of Idiopathic Parkinson Disease (PD). This apparent discrepancy is similar to what is observed in genetically determined parkinsonism, in which clinical profile, progression and L-DOPA responsiveness not always meet the paradigms of idiopathic forms. Despite family history, MND or marked cognitive impairment has not emerged, thus conforming an isolated L-DOPA responsive atypical parkinsonism till now. This case highlights some important elements connected to C9ORF72 expansion to bear in mind when dealing with patients: incomplete penetrance, complex genotype-phenotype correlations, wide range of clinical manifestations and overlapping, different response to treatments and prognosis. Indeed, while in the last few years some papers, mainly case reports, enlarged the clinical spectrum of C9ORF72-associated parkinsonian syndromes without ALS or FTD [2,7], studies on different populations of patients affected by atypical parkinsonian syndromes or PD, did not show an increased incidence of G4C2 hexanucleotide repeats expansion [9]. These data suggest that the pathogenic role of C9ORF72 expansion should be considered with caution in such pathologically and clinically different diseases [10]. In fact, while there was no evidence for over-representation of C9ORF72 expansions in patients with PD and confirmed a-synucleinopathy, neurodegeneration was shown in the substantia nigra of C9ORF72-related ALS cases [10]. Therefore, it is possible that despite the fact that C9ORF72 expansions are not a cause of classical PD, the neuropathology associated with C9ORF72-expansion can affect the substantia nigra and cause parkinsonism. Thus, C9ORF72 expansions can affect multiple brain areas which lead to different clinical consequences [11].
This opens also the question concerned to the repeat size at which the mutation becomes pathogenic in different clinical syndromes. The GGGGCC expansions have been described as pathogenic if they are N30 repeats. However, the clinical phenotype of ALS cases with 20–30 repeats are similar to those with N30 repeats [12], suggesting that the minimum number of repeats needed for pathogenicity may be smaller than the currently accepted cut-off. On the other hand, mutations with N30 repeats have also been reported in healthy individuals, as well as in those affected by other neurodegenerative diseases [11]. In our patients with parkinsonian features we found a relatively small expansion that may suggest a relationship with the relatively mild disease phenotype; nevertheless this correlation between expansion size, disease phenotypes and disease severity is still greatly controversial in literature and large cohort studies are needed to bring clarity on this topic.

In conclusion, in our case (as well as in the previously reported ones) we cannot exclude a fortuitous combination of parkinsonism and C9ORF72 intronic expansion (with possible future development of ALS-FTD), with a C9ORF72 role of “innocent bystander”, although the “atypical” phenotype could suggest a genetic imprint.

Therefore, genetic testing for C9ORF72 mutations should be considered in presence of pure atypical parkinsonism and a family history of ALS or FTD, with a cautiously interpretation of its role with patients and their families. These considerations may be useful in clinical practice for patients counselling and prognosis.

Author contributions

Dr. F. Cavallieri: conception and design of the study, acquisition of data, analysis and interpretation of data, drafting the article, final approval of the version to be submitted.

Dr. J. Mandrioli: conception and design of the study, acquisition of data, analysis and interpretation of data, revising the manuscript for important intellectual content, final approval of the version to be submitted.

Dr. F. Rosa.o: acquisition of data, analysis and interpretation of data, drafting the article, final approval of the version to be submitted.

Dr. S. Contardi: acquisition of data, analysis and interpretation of data, drafting the article, final approval of the version to be submitted.

Dr. A. Fasano: acquisition of data, analysis and interpretation of data, final approval of the version to be submitted.

Dr. E. Menozzi: acquisition of data, analysis and interpretation of data, drafting the article, final approval of the version to be submitted.

Dr. C. Caponnetto: acquisition of data, analysis and interpretation of data, drafting the article, final approval of the version to be submitted.

Prof. A. Chiò: conception and design of the study, drafting the article, revising the manuscript for important intellectual content, final approval of the version to be submitted.

Dr. F. Valzania: conception and design of the study, analysis and interpretation of data, drafting the article, revising the manuscript for important intellectual content, final approval of the version to be submitted.
Disclosures

Dr. F. Cavallieri reports no disclosures.

Dr. J. Mandrioli received research support from Regione Emilia Romagna (ERRALS: Emilia Romagna Register for ALS; Bando Area 2 Regione-Università), Associazione Italiana Sclerosi Laterale Amiotro.ca (Section of Modena), Agenzia Italiana di Ricerca per la Sclerosi Laterale Amiotro.ca (ARISLA); she served on the scientific advisory board for Italfarmaco.

Dr. F. Rosa.o reports no disclosures.

Dr. S. Contardi reports no disclosures.

Dr. A. Fasano reports no disclosures.

Dr. E. Menozzi reports no disclosures.

Dr. C. Caponnetto: reports no disclosures.

Prof. A. Chiò serves on the editorial advisory board of Amyotrophic Lateral Sclerosis and has received research support from the Italian Ministry of Health (Ricerca Finalizzata), Regione Piemonte (Ricerca Finalizzata), University of Turin, Fondazione Vialli e Mauro onlus, and the European Commission (Health Seventh Framework Programme); he serves on scientific advisory boards for Biogen Idec, Cytokinetics, Italfarmaco, Neuraltus and Mitsubishi.

Dr. F. Valzania reports no disclosures.

Conflict of interest

The authors report no conflicts of interest.

Written informed consent was obtained from the patient to be videoed for publication. Supplementary data associated with this article can be found in the online version, at 10.1016/j.jns.2017.04.027.